DIRS.INFO The most relevant business & tech news

☆ Morning Bid: Risk and rates moving in tandem
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +4 min

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., August 15, 2023. Or it may just be a series of idiosyncratic news events. Although both stock futures and bond yields edged back a touch again on Tuesday ahead of the bell, the fact they are moving in tandem ahead of a critical week for macro policy is notable. Overseas, European markets held up as this week's European Central Bank meeting is awaited with economists split on its outcome. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Brendan McDermid, Mike Dolan, Morgan Stanley, Farmer Bros, Ed Osmond Organizations: New York Stock Exchange, REUTERS, Big Tech, Tesla's, Dojo, Apple, chipmaker Qualcomm, Oracle, Reserve, Overseas, Central Bank, HK, Bank of, Smurfit Kappa, Treasury, Cable Corp, Altamira Therapeutics, Lesaka Technologies, Reuters Graphics, Reuters, Thomson Locations: New York City, U.S, China, London, Altamira

Sept 11 (Reuters) - Klaviyo is seeking a fully-diluted valuation of up to $8.4 billion in its initial public offering (IPO) in the United States, the marketing firm said on Monday, as it becomes the latest company to tap a growing wave of stock market listings. However, the company's proposed valuation is a climb-down from the $9.15 billion pre-money valuation at which Klaviyo last raised capital in 2021, reflecting a broader gloom in the technology startup ecosystem. Founded in 2012, Klaviyo helps store and analyze data for e-commerce brands that enables them to send out personalized marketing emails and messages to potential customers. Klaviyo posted 51% growth in revenue to $164.6 million for the three months ended June 30. The company is expected to debut in September, a busy month for stock market listings that could serve as a litmus test for other companies looking to go public.

Persons: Andrew Bialecki, Klaviyo, AllianceBernstein, Goldman Sachs, Morgan Stanley, Sri Hari, Manya, Niket Nishant, Shweta Agarwal, Maju Samuel Organizations: Arm Holdings, Neumora Therapeutics, Summit Partners, BlackRock, New York Stock Exchange, Citigroup, underwriters, Sri, Manya Saini, Thomson Locations: United States, Boston, United Kingdom, Australia, Bengaluru

☆ Cramer: These things could soon break the bulls' way, plus 4 stocks to buy
▼ + stars: | 2023-09-10 | by ( Jim Cramer | ) www.cnbc.com time to read: +6 min

If you don’t know a soul that is bullish — and I mean flat-out positive — you may need some new friends. I say I am a naked opportunist and I feel naked and alone right now in saying we might have a bunch of things that could break the bulls' way. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: —, We’ve, sotto, Shawn Fain, Leon Trotsky, Fain, Lululemon, LULU, Robert Bradway, Amgen, Lina Khan, Khan, Trump, Estee Lauder, Morgan Stanley, Jim Cramer's, Jim Cramer, Jim, Virginia Sherwood Organizations: Federal Reserve, Softbank's Arm Holdings, United Auto Workers, UAW, Federal Trade, Activision Blizzard, Horizon Therapeutics, FTC, Apple, GE HealthCare, Disney, Bausch Health, Honeywell, Jim Cramer's Charitable, CNBC, NYSE Locations: Russian, U.S, Wells

☆ VC Ford Smith used psychedelics and biohacking to pull himself out of a deep depression. Here's why he's backing more startups in the space.
▼ + stars: | 2023-09-07 | by ( Samantha Stokes | ) www.businessinsider.com time to read: +7 min

His experience inspired him to focus his investment firm on backing psychedelic startups. But VCs, including Smith, are still betting big on startups in the space that seem especially promising. It wasn't until he tried psychedelics — including Ayahuasca, a plant-derived hallucinogenic drink, and iboga, an African root bark — that his mental health finally improved. Energized by his own experience, Smith reworked his cannabis-focused VC firm Ultranative into a one-stop-shop for psychedelic startups. Smith and Ultranative are far from the only investors pumping money into psychedelic startups.

Persons: Ford Smith, wean, South America —, Ayahuasca, Ultranative, Smith, didn't, Lyme, psychedelics, Rick Doblin, he's Organizations: innovating, Venture, Anonymous, Multidisciplinary Association for Psychedelic Studies, pharma, FDA, PsyMed Ventures, Lionheart Ventures, Iter Investments, Neo Kuma Ventures, Therapeutics Locations: Austin, South America, U.S, Oregon, Colorado, psychedelics, Texas, Los Angeles, Massachusetts

☆ Here are the most overbought and oversold major global stocks, including tech and banking names
▼ + stars: | 2023-09-06 | by ( Weizhen Tan | ) www.cnbc.com time to read: +1 min

Global stocks, too, were bumpy last month: The MSCI World index fell in the middle of the month before paring some losses toward the end. The relative strength index (RSI), which measures the magnitude and speed of price moves, can be used by investors to determine if shares are overbought or oversold. CNBC Pro screened the MSCI World index for major global stocks that are among the most overbought and oversold, based on their 14-day RSI. Oversold names These names are among the most oversold global stocks, spanning health care, autos and banking. Overbought names These names are among the most oversold global stocks, including some in the tech sector.

Persons: It's, Johnson, Japan's, BYD Organizations: CNBC Pro, Global, Volkswagen, BMW, CVS Health, Johnson, UnitedHealth Group, IBM, Dell, Cisco, Horizon Therapeutics Locations: U.S

☆ HSBC says this biopharma company can jump 25% despite 'patent cliff'
▼ + stars: | 2023-09-06 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Amgen has a promising growth outlook despite facing a "substantial patent cliff," according to HSBC. While some very old products are finally facing patent cliffs it will likely be gradual and a broadened portfolio allows for continued growth," analyst Morten Herholdt wrote in a Wednesday note. Amgen is set to lose exclusivity on patents for drugs that make up about three-quarters of the company's sales. The company's acquisition of Horizon Therapeutics will also help it extend sales and pipeline into the rare diseases market, Herholdt added. Due to the current investor skepticism with the looming patent cliff, Amgen shares are trading at an "undemanding" earnings multiple, according to the analyst.

Persons: Amgen, Morten Herholdt, Herholdt, —, Michael Bloom Organizations: HSBC, Horizon Therapeutics Locations: Tuesday's

“With us, you know what you get, which is rare nowadays!” Alexandre Edelmann, head of Presence Switzerland, a government agency that promotes the country abroad, says in an email. “People love our country without always knowing why,” says Jacques Pitteloud, Switzerland’s ambassador to the U.S. and a veteran diplomat. We are constantly leading the pack in terms of innovation.”This is evident in the prominent role Switzerland plays in some key areas of the global economy. Acknowledging "the elephant in the room," Pitteloud says Switzerland and the EU have "a complex relationship." And as a relatively small, landlocked country in which many areas are difficult to inhabit due to terrain, Switzerland is facing challenges related to population and resources.

Persons: Roger Federer, Philippe, –, Alexandre Edelmann, ”, Jacques Pitteloud, Pitteloud, ” Delphine Donné, Ruag, yearslong, ” Georg Klingler, Donné Organizations: Wimbledon, U.S . News, European Union, Bank, Presence Switzerland, Nestle, Roche, Novartis, Atlas, Logitech, ETH Zurich, Zurich University of Applied Sciences, EU, Greenpeace, Associated Press Locations: Switzerland, Europe, U.S, Swiss, France, China, Canada, Lausanne, Ukraine, Greenpeace Switzerland

The California bill would make gender affirmation one factor among many that courts already have to consider in custody proceedings, including whether a parent has been abusive and how much contact the child has with the parents. The bill would not require judges to prioritize whether a parent affirms their child's gender identity over other factors. The state Senate passed the resolution, and it now heads to the Assembly. State Sen. Shannon Grove, a Republican from Bakersfield, said she didn’t think other states would agree to that. The bipartisan California bill would not legalize the sale of the drugs.

Persons: Democratic Sen, Scott Wiener, they’ve, ” Wiener, ”, Sen, Kelly Seyarto, ” Seyarto, Gavin Newsom, Assemblymember Lori Wilson, Wilson, “, Alexis Sanchez, Sanchez, Newsom, Aisha Wahab, Wiener, State Sen, Shannon Grove, DECRIMINALIZING, it’s, Bill Essayli, Adam Beam, Nguyễn, ___ Sophie Austin, Austin @sophieadanna Organizations: Democratic, Republican, Democratic Gov, Sacramento LGBT Community Center, San Francisco, State, ., Associated Press, America Statehouse News Initiative, America Locations: SACRAMENTO, Calif, California, San Francisco, Southern California, U.S, Bakersfield, DECRIMINALIZING PSYCHEDELICS California, . Oregon, Colorado

☆ Analysis: FTC settlement could shelter Amgen from US price cuts, taxes
▼ + stars: | 2023-09-05 | by ( Deena Beasley | ) www.reuters.com time to read: +5 min

An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. With Horizon, Amgen acquires drugs that won't be affected by new U.S. negotiation requirements for blockbuster medications as well as possible tax advantages stemming from Horizon's headquarters in Ireland. Analysts said the Horizon deal could also help Amgen's tax situation. The United States has largely eliminated once-lucrative corporate tax benefits for pharmaceutical manufacturing operations in Puerto Rico, a U.S. territory. Horizon offers Amgen "potentially a better tax jurisdiction related to Irish manufacturing plants ... Amgen has a new manufacturing process they could potentially move there," Cowen's Werber said.

Persons: Robert Galbraith, Abiel Garcia, John Kness, Donald Trump, Garcia, Evan Seigerman, Lina Khan, Cowen, Biden, Michael Yee, Amgen, Cowen's Werber, Deena Beasley, Peter Henderson, Paul Simao Organizations: REUTERS, U.S . Federal Trade, Horizon Therapeutics, U.S, District, Federal, Activision, Horizon, Amgen, BMO Capital Markets, FTC, Reuters, U.S . Food, Drug Administration, Jefferies, Medicare, Internal Revenue Service, United, Thomson Locations: South San Francisco , California, Amgen, Kesselman, Ireland, U.S, Puerto Rico, United States, Irish

☆ The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals
▼ + stars: | 2023-09-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

That includes the agency's examination of Pfizer 's proposed $43 billion purchase of cancer drug developer Seagen . Some also speculated that the restrictions imposed on Amgen as part of the settlement could have implications for other deals. The FTC's lawsuit against Amgen in May was the agency's first legal challenge to a pharmaceutical buyout in 14 years. The settlement agreement prohibits Amgen from bundling any of its products with two of Horizon's blockbuster drugs, among other restrictions. Still, some analysts said the restrictions suggest the FTC could apply similar rules to other buyouts in the future.

Persons: Amgen, William Blair, Matt Phipps, Robyn Karnauskas, baring, Nathan Ray, West, Biden, Evan Seigerman Organizations: Federal Trade Commission, Horizon Therapeutics, Pfizer, FTC, West Monroe, Amgen, Pharmaceutical, Pharma, BMO Capital Locations: Amgen

☆ Nestle divests peanut allergy business Palforzia
▼ + stars: | 2023-09-04 | by ( ) www.reuters.com time to read: +1 min

Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics, based in Brisbane, California, in this handout obtained by Reuters on February 5, 2020. Aimmune Therapeutics/Handout via REUTERS/File Photo Acquire Licensing RightsZURICH, Sept 4 (Reuters) - Nestle (NESN.S) has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division. Nestle said it has offloaded Palforzia to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. Nestle will receive milestone payments and ongoing royalties from Stallergenes Greer, it said. Reporting by John Revill, Editing by Friederike HeineOur Standards: The Thomson Reuters Trust Principles.

Persons: Nestle, Stallergenes Greer, John Revill, Friederike Heine Our Organizations: Aimmune Therapeutics, Reuters, REUTERS, Rights, Nestle, Thomson Locations: Brisbane , California, Swiss

☆ 'Robot pills' could one day help patients avoid needles. The stocks are cheap, but risky
▼ + stars: | 2023-09-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

That's where a number of early-stage drug delivery companies come in — and most are flying under investors' radar. Drug delivery tends to be a "roll-up sector," explained Edward Nash, an analyst at Canaccord Genuity. Nash recently looked at four companies operating in drug delivery: Rani Therapeutics , Biora Therapeutics , Avalyn Pharma and Elektrofi. At the moment, the most effective GLP-1 medications for weight loss are delivered via a subcutaneous injection. The verstility of the Rani pill also is encouraging, according to Harrison, since it could be used with a wide range of drugs.

Persons: that's, Edward Nash, Nash, Rani, FactSet, Talat Imran, Eli Lilly, Evercore, Lilly, Genuity's Nash, Julian Harrison, Rani's, Harrison, Cantor Fitzgerald, Olivia Brayer, Imran, We're Organizations: Big Pharma, Therapeutics, Biora Therapeutics, Avalyn Pharma, CNBC, Novo Nordisk, Novo, European Union, Food and Drug Administration, Celltrion Locations: —

☆ FTC Reaches Agreement With Amgen Over $27.8 Billion Deal for Horizon Therapeutics
▼ + stars: | 2023-09-01 | by ( Dave Michaels | Joseph Walker | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/ftc-settles-with-amgen-over-27-8-billion-deal-for-horizon-therapeutics-b96a2d69

Persons: Dow Jones Organizations: ftc

☆ Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle
▼ + stars: | 2023-09-01 | by ( Dave Michaels | Joseph Walker | ) www.wsj.com time to read: 1 min

Persons: Dow Jones Organizations: ftc

☆ FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisition
▼ + stars: | 2023-09-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Friday said it has reached a deal with drug giant Amgen to allow the company's $27.8 billion purchase of Horizon Therapeutics to move forward. The two companies now expect to close the acquisition – Amgen's largest ever – early in the fourth quarter of this year, a spokesperson for Amgen said. But the agreement announced Friday still imposes restrictions on Amgen to address key concerns the FTC raised in its suit. That practice involves offering rebates or discounts on its existing products to pressure insurers and pharmacy benefit managers into favoring the Horizon products. A Horizon spokesperson did not immediately respond to a request for comment.

Persons: Amgen Organizations: Federal Trade Commission, Horizon Therapeutics, FTC Locations: Thousand Oaks , California, California , Illinois, Minnesota , New York, Washington, Wisconsin

☆ Amgen settles with the FTC over $28 billion deal
▼ + stars: | 2023-09-01 | by ( Eva Rothenberg | ) edition.cnn.com time to read: +2 min

In May, the FTC filed a complaint in the US District Court for the Northern District of Illinois to stop the deal from going ahead, alleging that it was anti-competitive. The lawsuit involved Horizon’s Tepezza, used to treat thyroid eye disease, and Kystexxa, used to treat chronic refractory gout. The FTC’s concern was that, by acquiring these products, Amgen would stifle competition by making it harder for consumers to have access to cheaper medicines if they were developed by competitors. It also needs to gain approval from the FTC before acquiring any other companies that manufacture these types of medicines. The two companies are expected to finalize the merger later this year, according to Amgen.

Persons: Amgen, Horizon’s, “ Organizations: New, New York CNN, Federal Trade Commission, Horizon Therapeutics, Court, Northern, Northern District of, FTC Locations: New York, Northern District, Northern District of Illinois

An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013. Under the FTC settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, and from using any product rebate or contract term to exclude or disadvantage products that would compete with those drugs. It also prevents Amgen from buying any competitors to the two Horizon drugs without the FTC's permission. The lawsuit had raised concerns over increased oversight on mergers and acquisitions in a sector that often turns to consolidation to power future growth as patents on older treatments expire. Shares of Seagen Inc (SGEN.O), which is in the process of being acquired by Pfizer (PFE.N), rose 1.5%.

Persons: Robert Galbraith, Lina Khan, Robyn Karnauskus, Khan, Manas Mishra, David Shepardson, Devika Organizations: REUTERS, U.S . Federal Trade Commission, Horizon Therapeutics, FTC, Seagen Inc, Pfizer, Thomson Locations: South San Francisco , California, Amgen, Bengaluru, Washington

☆ Would you pay hundreds of dollars for an app your doctor prescribed? Buzzy digital therapeutics could make you healthier — but your insurer probably won't cover them.
▼ + stars: | 2023-09-01 | by ( Natalie Rahhal | ) www.businessinsider.com time to read: +8 min

Apps such as Somryst — known as prescription digital therapeutics — aim to raise the bar for personal healthcare delivered via smartphone. Digital therapeutics show promise for treating IBS and insomniaFunding for digital therapeutics surged by 133% between 2020 and 2021, and the sector's global value is estimated to grow from roughly $7 billion to about $28 billion from now to 2030, Fortune Business Insights reported. In fact, many insurance companies want years of data on real-world use before covering digital therapeutics, Insider previously reported. While there are free nonprescription DTxs available from sources such as the Department of Veterans Affairs, those aren't cleared by the FDA, and privately made prescription digital therapeutics often cost hundreds of dollars. "Digital therapeutics are meant to increase access to care.

Persons: Charlotte Jee, Jee, Corey McCann, John Torous, Beth Israel, they're, Torous, They're, AspyreRx, Mark Berman, hadn't Organizations: Healthcare, Morning, MIT Technology, National Health Service, Food and Drug Administration, Pear Therapeutics, Harvard Medical, Beth Israel Deaconess Medical, Fortune Business, FDA, Better Therapeutics, Disease Control, Department of Health, Human Services, of Health, Department of Veterans Affairs, Aetna

☆ 'Barbie Botox' goes viral but doctors inject caution
▼ + stars: | 2023-09-01 | by ( Leroy Leo | ) www.reuters.com time to read: +4 min

But since the "Barbie" movie released in July, there has been an uptick in demand for use as a cosmetic procedure. Meanwhile, Revance and Evolus Inc (EOLS.O), which make similar toxins under the brand Daxxify and Jeuveau, respectively, told Reuters that though "Barbie Botox" has picked up in recent months, they do not see the trend significantly boosting sales. However, the doctors said they were concerned about a rise in use among younger women - and six doctors warned that procedures by underqualified staff at some medispas raised the risk of complications. Doctors also stressed the risk with administration by people who may not be properly qualified, especially at medispas where there is little oversight. "The science isn't quite there yet, in order to support the clinical profile of it," said Evolus CEO David Moatazedi.

Persons: Margot Robbie, BarbieBotox, that's, Barbie, Dustin Sjuts, Scot Glasberg, Revance, Shilpi Kheterpal, Kheterpal, Doctors, Melissa Levoska, David Moatazedi, Leroy Leo, Sriraj Organizations: Therapeutics, Reuters, Plastic Surgery Foundation, U.S . Food, Drug Administration, Evolus Inc, AbbVie Inc, Cleveland Clinic, Icahn School of Medicine, Thomson Locations: New York, U.S, medispas, Mount Sinai, Bengaluru

People are seen on Wall Street outside the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2021. Focus now shifts to a report on the personal consumption expenditures price index, the Fed's preferred inflation gauge, to be released on Thursday, and non-farm payrolls data due on Friday. According to preliminary data, the S&P 500 (.SPX) gained 27.49 points, or 0.62%, to end at 4,433.20 points, while the Nasdaq Composite (.IXIC) gained 114.49 points, or 0.84%, to 13,705.13. Micron's and Intel's shares gained for much of the session. Horizon's shares rose.

Persons: Brendan McDermid, Goldman Sachs, Jerome Powell, Powell didn't, Ross Mayfield, Gina Raimondo, Wang Wentao, Shristi Achar, Noel Randewich, Shounak Dasgupta, David Gregorio Our Organizations: New York Stock Exchange, REUTERS, Investment, Baird, Nvidia, Creative Planning, Nasdaq, Dow Jones, JD.com, Baidu, U.S . Commerce, Intel, Micron, Chinese Commerce, U.S . Federal Trade Commission, Horizon Therapeutics, Thomson Locations: New York City, U.S, China, Bengaluru, Oakland, Calif

People are seen on Wall Street outside the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2021. Horizon's shares rose 5.5%. Advancing issues outnumbered decliners for a 3.82-to-1 ratio on the NYSE and a 1.78-to-1 ratio on the Nasdaq. The S&P index recorded seven new 52-week highs and no new low, while the Nasdaq recorded 43 new highs and 101 new lows. Reporting by Shristi Achar A and Amruta Khandekar in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Stocks, Jerome Powell, Roosevelt Bowman, Gina Raimondo, Wang Wentao, Goldman Sachs, decliners, Shristi Achar, Shounak Dasgupta Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Bernstein Private Wealth Management, Traders, Fed, Nvidia, U.S, Baidu, U.S . Commerce, Intel, Micron, Chinese Commerce, Intel's, Dow Jones, U.S . Federal Trade Commission, Horizon Therapeutics, Creative Planning, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

People are seen on Wall Street outside the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2021. Focus now shifts to a report on the personal consumption expenditures price index, the Fed's preferred inflation gauge, which is set to be released on Thursday and the non-farm payrolls data due on Friday. ET, Dow e-minis were up 74 points, or 0.22%, S&P 500 e-minis were up 6.5 points, or 0.15%, and Nasdaq 100 e-minis were up 41.5 points, or 0.28%. Horizon Therapeutics' shares rose 5.2%. Reporting by Shristi Achar A and Amruta Khandekar in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Stocks, Jerome Powell, Mark Haefele, Powell's Jackson, Shristi Achar, Shounak Dasgupta Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Fed, UBS Global Wealth Management, U.S, PDD Holdings, Baidu, Dow e, U.S . Federal Trade Commission, Horizon Therapeutics, Therapeutics, Thomson Locations: New York City, U.S, China, Xpeng, Bengaluru

☆ Stocks making the biggest moves midday: RPT Realty, Mister Car Wash, Boston Scientific, 3M and more
▼ + stars: | 2023-08-28 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

RPT Realty — RPT Realty shares surged 17% after Kimco Realty, an operator of open-air shopping centers, said it would acquire the real estate investment trust in a roughly $2 billion all-stock deal. Mister Car Wash — The car wash stock advanced 6.1% on the back of an upgrade to overweight from neutral by Piper Sandler. Alibaba Group , JD.com — Alibaba and JD.com each added more than 2% after the Chinese government announced measures to boost its stock market, including reducing a tax on trading. Xpeng — Shares of the Chinese electric car company jumped 5.3% after the firm said it is buying Didi's smart electric car development business in an exchange of shares worth $744 million. Meanwhile, Xpeng said it plans to develop an electric car for launch next year under a new mass market brand.

Persons: Conor Flynn, Piper Sandler, — CrowdStrike, Morgan Stanley, —, Xpeng, Wells, Sarah Akers, Micron Technology — Stocks, — CNBC's Alexander Harring, Hakyung Kim, Yun Li, Jesse Pound, Pia Singh, Samantha Subin Organizations: RPT, Realty, Kimco Realty, Boston, Boston Scientific, Bloomberg, 3M, Akero Therapeutics, Therapeutics, UBS, Alibaba, Micron Technology —, Micron Technology, Marvell Technology, Semiconductors Locations: Xpeng

☆ Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
▼ + stars: | 2023-08-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

FRANKFURT, Aug 28 (Reuters) - Bayer (BAYGn.DE) said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson’s disease symptoms in an early 12-patient trial. The German drugmaker announced the trial had succeeded in a brief summary in June, saying it was a first for a stem-cell Parkinson's therapy, but held back details for a medical conference. The five participants on a lower dose experienced 0.72 hours longer per day with well-controlled symptoms on average and the time of worsening symptoms was 0.75 hours shorter per day for them. For BlueRock's experimental therapy, the researchers took human pluripotent embryonic stem cells and transformed them into dopamine-producing nerve cells. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.

Persons: BlueRock, Christian Rommel, Bayer's, Britain's, Ludwig Burger, Susan Fenton Organizations: FRANKFURT, Bayer, U.S, drugmaker, International Congress, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, Thomson Locations: Copenhagen, Denmark, Australia, United States

People are seen on Wall Street outside the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2021. The S&P 500 communication services (.SPLRCL) and technology (.SPLRCT) sectors led gains among the 11 major S&P sub-indexes, rising 1.2% and 0.8% respectively. Horizon's shares rose 5.8%. Advancing issues outnumbered decliners for a 5.47-to-1 ratio on the NYSE and a 2.95-to-1 ratio on the Nasdaq. Reporting by Shristi Achar A and Amruta Khandekar in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Stocks, Jerome Powell, Peter Andersen, Gina Raimondo, Wang Wentao, decliners, Shristi Achar, Shounak Dasgupta Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Microsoft, Andersen Capital Management, Traders, U.S, PDD Holdings, Baidu, U.S . Commerce, Intel, Micron, Chinese Commerce, Intel's, Dow Jones, Xpeng, U.S . Federal Trade Commission, Horizon Therapeutics, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

Search resuls for: "THERAPEUTICS"

25 mentions found